p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies

SA Wander, D Zhao, JM Slingerland - Clinical cancer research, 2011 - AACR
Clinical cancer research, 2011AACR
Phosphorylation of the cyclin-dependent kinase inhibitor p27 by upstream mitogenic
signaling pathways regulates its stability, localization, and biological function. In human
cancers, loss of the antiproliferative action of p27 can arise through reduced protein levels
and/or cytoplasmic mislocalization, leading to increased cell proliferation and/or cell
migration, respectively. Reduced p27 expression levels and p27 mislocalization have
potential prognostic and therapeutic implications in various types of human cancers. This …
Abstract
Phosphorylation of the cyclin-dependent kinase inhibitor p27 by upstream mitogenic signaling pathways regulates its stability, localization, and biological function. In human cancers, loss of the antiproliferative action of p27 can arise through reduced protein levels and/or cytoplasmic mislocalization, leading to increased cell proliferation and/or cell migration, respectively. Reduced p27 expression levels and p27 mislocalization have potential prognostic and therapeutic implications in various types of human cancers. This review highlights mechanisms of functional deregulation of p27 by oncogenic signaling that provide an important molecular rationale for pathway targeting in cancer treatment. Clin Cancer Res; 17(1); 12–8. ©2010 AACR.
AACR